Zura Bio Launches Groundbreaking Phase 2 Trial for Novel Dual-Pathway Autoimmune Treatment
Zura Bio launches TibuSURE, a global Phase 2 study evaluating tibulizumab for systemic sclerosis in adults, targeting both anti-BAFF and IL-17 pathways for deeper efficacy.
Highlighted Terms
Related News
Zura Bio Launches Groundbreaking Phase 2 Trial for Novel Dual-Pathway Autoimmune Treatment
Zura Bio launches TibuSURE, a global Phase 2 study evaluating tibulizumab for systemic sclerosis in adults, targeting both anti-BAFF and IL-17 pathways for deeper efficacy.